Literature DB >> 28603559

Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis.

Ikuo Tsunoda1, Fumitaka Sato1, Seiichi Omura1, Mitsugu Fujita1, Namie Sakiyama1, Ah-Mee Park1.   

Abstract

Theiler's murine encephalomyelitis virus (TMEV) infection has been used as a viral model for multiple sclerosis (MS), as TMEV can induce chronic inflammatory demyelinating lesions with viral persistence in the spinal cord of SJL/J mice. In contrast, when C57BL/6 mice are infected with TMEV, the mice can clear the virus from the central nervous system (CNS), without viral persistence or demyelination, but develop seizures and hippocampal sclerosis, which has been used as a viral model for seizures/epilepsy. In the two TMEV-induced CNS disease models, not only viral infection, but also immune responses contribute to the pathogenesis. Interestingly, acquired immunity plays an effector role in the MS model, whereas innate immunity appears to contribute to the development of seizures. Recently, we have established the third TMEV-induced disease model, a mouse model for viral myocarditis, using C3H mice. TMEV-induced myocarditis is a triphasic disease, which mimics human myocarditis; phase I, mediated by viral replication in the heart and innate immunity; phase II, mediated by acquired immunity; and phase III, resulted from cardiac fibrosis. The genetic susceptibility to the aforementioned three models (MS, seizures and myocarditis) differs among mouse strains. We have compared and contrasted the three models induced by one single pathogen, TMEV, particularly in regard to the roles of T helper cells and natural killer T cells, which will give an insight into how interactions between the immune system and the host's genetic background determine the tissue tropism of virus and the development of virus-induced organ-specific immunopathology.

Entities:  

Keywords:  Picornaviridae infections; Th17 cells; animal models; central nervous system demyelinating diseases; experimental autoimmune encephalomyelitis

Year:  2016        PMID: 28603559      PMCID: PMC5464738          DOI: 10.1111/cen3.12341

Source DB:  PubMed          Journal:  Clin Exp Neuroimmunol        ISSN: 1759-1961


  119 in total

1.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

2.  Incidence of myocarditis. A 10-year autopsy study from Malmö, Sweden.

Authors:  M B Gravanis; N H Sternby
Journal:  Arch Pathol Lab Med       Date:  1991-04       Impact factor: 5.534

3.  Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension.

Authors:  Marc S Sabatine; Kian-Keong Poh; Jessica L Mega; Jo-Anne O Shepard; James R Stone; Matthew P Frosch
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

4.  Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B.

Authors:  I Tsunoda; Y Wada; J E Libbey; T S Cannon; F G Whitby; R S Fujinami
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 5.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

6.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

7.  A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.

Authors:  Tobias Derfuss; François Curtin; Claudia Guebelin; Claire Bridel; Maria Rasenack; Alain Matthey; Renaud Du Pasquier; Myriam Schluep; Jules Desmeules; Alois B Lang; Hervé Perron; Raphael Faucard; Hervé Porchet; Hans-Peter Hartung; Ludwig Kappos; Patrice H Lalive
Journal:  J Neuroimmunol       Date:  2015-05-20       Impact factor: 3.478

8.  Subclinical left ventricular dysfunction in multiple sclerosis.

Authors:  Ferit Akgül; Ismet McLek; Taşkin Duman; Ergün Seyfelì; Tunzale Seydaliyeva; Fatih Yalçin
Journal:  Acta Neurol Scand       Date:  2006-08       Impact factor: 3.209

9.  Observations on encephalomyelitis of mice (DA strain).

Authors:  J B DANIELS; A M PAPPENHEIMER; S RICHARDSON
Journal:  J Exp Med       Date:  1952-12       Impact factor: 14.307

Review 10.  "Microglial nodules" and "newly forming lesions" may be a Janus face of early MS lesions; implications from virus-induced demyelination, the Inside-Out model.

Authors:  Fumitaka Sato; Nicholas E Martinez; Elaine Cliburn Stewart; Seiichi Omura; J Steven Alexander; Ikuo Tsunoda
Journal:  BMC Neurol       Date:  2015-10-24       Impact factor: 2.474

View more
  8 in total

1.  Helicobacter pylori and gut microbiota in multiple sclerosis versus Alzheimer's disease: 10 pitfalls of microbiome studies.

Authors:  Ah-Mee Park; Seiichi Omura; Mitsugu Fujita; Fumitaka Sato; Ikuo Tsunoda
Journal:  Clin Exp Neuroimmunol       Date:  2017-07-23

2.  Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.

Authors:  Katayoun Ayasoufi; Christian K Pfaller; Laura Evgin; Roman H Khadka; Zachariah P Tritz; Emma N Goddery; Cori E Fain; Lila T Yokanovich; Benjamin T Himes; Fang Jin; Jiaying Zheng; Matthew R Schuelke; Michael J Hansen; Wesley Tung; Ian F Parney; Larry R Pease; Richard G Vile; Aaron J Johnson
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

3.  Virus-triggered spinal cord demyelination is followed by a peripheral neuropathy resembling features of Guillain-Barré Syndrome.

Authors:  Eva Leitzen; Barbara B Raddatz; Wen Jin; Sandra Goebbels; Klaus-Armin Nave; Wolfgang Baumgärtner; Florian Hansmann
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

4.  Screening of prototype antiseizure and anti-inflammatory compounds in the Theiler's murine encephalomyelitis virus model of epilepsy.

Authors:  Cameron S Metcalf; Fabiola Vanegas; Tristan Underwood; Kristina Johnson; Peter J West; Misty D Smith; Karen S Wilcox
Journal:  Epilepsia Open       Date:  2021-11-03

5.  Genetic and immunological contributors to virus-induced paralysis.

Authors:  Aracely A Perez Gomez; Moumita Karmakar; Raymond J Carroll; Koedi S Lawley; Katia Amstalden; Colin R Young; David W Threadgill; C Jane Welsh; Candice Brinkmeyer-Langford
Journal:  Brain Behav Immun Health       Date:  2021-11-26

6.  Acute Disseminated Encephalomyelitis with Seizures and Myocarditis: A Fatal Triad.

Authors:  Hanne Lademann; Astrid Bertsche; Axel Petzold; Fred Zack; Andreas Büttner; Jan Däbritz; Christina Hauenstein; Erik Bahn; Christian Spang; Daniel Reuter; Philipp Warnke; Johannes Ehler
Journal:  Medicina (Kaunas)       Date:  2020-06-04       Impact factor: 2.430

7.  Comparison of Theiler's Murine Encephalomyelitis Virus Induced Spinal Cord and Peripheral Nerve Lesions Following Intracerebral and Intraspinal Infection.

Authors:  Wen Jin; Eva Leitzen; Sandra Goebbels; Klaus-Armin Nave; Wolfgang Baumgärtner; Florian Hansmann
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

8.  Transcriptome analysis following neurotropic virus infection reveals faulty innate immunity and delayed antigen presentation in mice susceptible to virus-induced demyelination.

Authors:  Malgorzata Ciurkiewicz; Stefan Floess; Michael Beckstette; Maren Kummerfeld; Wolfgang Baumgärtner; Jochen Huehn; Andreas Beineke
Journal:  Brain Pathol       Date:  2021-07-06       Impact factor: 6.508

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.